The importance of clinic attendance in the first six months on antiretroviral treatment: A retrospective analysis at a large public sector HIV clinic in South Africa

Journal of the International AIDS Society

Volumn 13, Issue 1, 2010, Pages

  Brennan, Alana T ^a,b,c   Maskew, Mhairi ^e   Sanne, Ian ^d,e   Fox, Matthew P ^a,b,c,f  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b Health Economics and Epidemiology Research Office   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d RIGHT TO CARE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOUTH AFRICA; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; IMMUNOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PSYCHOLOGICAL ASPECT; UTILIZATION REVIEW;

ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PUBLIC SECTOR; RETROSPECTIVE STUDIES; SOUTH AFRICA; YOUNG ADULT;

EID: 78649754334     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-13-49     Document Type: Article

References (40)

1. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. RP Walensky LL Wolf R Wood MO Fofana KA Freedberg NA Martinson AD Paltiel X Anglaret MC Weinstein E Losina, J Infect Dis 2008 197 1324 1332 10.1086/587184 18422445 (Pubitemid 351632764)
2. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. SD Lawn AD Harries X Anglaret L Myer R Wood, AIDS 2008 22 1897 1908 10.1097/QAD.0b013e32830007cd 18784453
3. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. P Braitstein MW Brinkhof F Dabis M Schechter A Boulle P Miotti R Wood C Laurent E Sprinz C Seyler DR Bangsberg E Balestre JA Sterne M May M Egger, Lancet 2006 367 817 824 10.1016/S0140-6736(06)68337-2 16530575
4. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. M Brinkhof F Dabis L Myer D Bangsberg A Boulle D Nash M Schechter C Laurent O Keiser M May E Sprinz M Egger X Anglaret, WHO Bulletin 2008 86 497 576
5. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. G Chne JA Sterne M May D Costagliola B Ledergerber AN Phillips F Dabis J Lundgren A D'Arminio Monforte F de Wolf R Hogg P Reiss A Justice C Leport S Staszewski J Gill G Fatkenheuer ME Egger, Lancet 2003 362 679 686 12957089
6. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virologic response: a 3-year follow-up study. MP Carrieri F Raffi C Lewden A Sobel C Michelet V Cailleton G Chne C Leport JP Moatti B Spire, Antivir Ther 2003 8 585 594 14760892
7. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. L Ferradini A Jeannin L Pinoges J Izopet D Odhiambo L Mankhambo G Karungi E Szumilin S Balandine G Fedida MP Carrieri B Spire N Ford JM Tassie PJ Guerin C Brasher, Lancet 2006 367 1335 1342 10.1016/S0140-6736(06)68580-2 16631912
8. Expanding access to antiretroviral therapy through the public sector - the challenge of retaining patients in long-term primary care. L Myer W el Sadr, S Afr Med J 2004 94 273 274 15150939
9. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. JK Yu SC Chen KY Wang CS Chang SD Makombe EJ Schouten AD Harries, Bull World Health Organ 2007 85 550 554 10.2471/BLT.06.037739 17768504
10. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. SD Lawn L Myer G Harling C Orrell LG Bekker R Wood, Clin Infect Dis 2006 43 770 776 10.1086/507095 16912954
11. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. JB Nacheqa EJ Mills M Schechter, Curr Opin HIV/AIDS 2010 5 1 70 77 10.1097/COH.0b013e328333ad61
12. Antiretroviral adherence in a resource-poor setting. C Orrell, Curr HIV/AIDS Rep 2005 2 4 171 176 10.1007/s11904-005-0012-8 16343374
13. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. EM Garnder WJ Burman ME Maravi AJ Davidson, AIDS 2010 24 3 395 403 10.1097/QAD.0b013e328335cd8a 20099399
14. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. GM Lucas RE Chaisson RD Moore, Ann Intern Med 1999 131 81 87 10419445
15. Highly active antiretroviral therapy outcomes in a primary care clinic. DA Rastegar MI Fingerhood DR Jasinski, AIDS Care 2003 15 231 237 10.1080/0954012031000068371 12856344
16. Missed Visit and Mortality among Patients Establishing Initial Outpatient HIV Treatment. MJ Mugavero HY Lin JH Willig AO Westfall KB Ulett JS Routman S Abroms JL Raper MS Saag JJ Allison, Clin Infect Dis 2009 48 2 248 256 10.1086/595705 19072715
17. Retention in care: a challenge to survival with HIV infection. TP Giordano AL Gifford AC White Jr ME Suarez-Almazor L Rabeneck C Hartman LI Backus LA Mole RO Morgan, Clin Infect Dis 2007 44 1493 1499 10.1086/516778 17479948
18. Non-adherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community based HIV primary care clinic. MB Berg SA Safren MJ Mimiaga C Grasso S Boswell KH Mayer, AIDS Care 2005 17 7 902 907 16120506
19. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. A Sethi D Celentano S Gange R Moore J Gallant, Clin Infect Dis 2003 37 8 1112 1118 10.1086/378301 14523777
20. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. H Valdez MM Lederman I Woolley CJ Walker LT Vernon A Hise BM Gripshover, Arch Intern Med 1999 159 15 1771 1776 10.1001/archinte.159.15.1771 10448781
21. Chronic Disease Self-Management and adherence to HIV Medications. AL Gifford EJ Groessl, JAIDS 2002 31 163 S166 12562043
22. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. D Nash M Katyal MW Brinkhof O Keiser M May R Hughes F Dabis R Wood E Sprinz M Schechter M Egger, AIDS 2008 22 17 2291 2302 10.1097/QAD.0b013e3283121ca9 18981768
23. National Department of Health, Republic of South Africa, National Antiretroviral Treatment Guidelines Jacana Publishers 2004
24. Effectiveness of antiretroviral treatment in a South African program: a cohort study. LR Fairall MO Bachmann GM Louwagie C van Vuuren P Chikobvu D Steyn GH Staniland V Timmerman M Msimanga CJ Seebregts A Boulle R Nhiwatiwa ED Bateman MF Zwarenstein RD Chapman, Arch Intern Med 2008 168 86 93 10.1001/archinternmed.2007.10 18195200
25. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. MP Fox A Brennan M Maskew P MacPhail I Sanne, Trop Med Int Health 2010 15 4 405 413 20180931
26. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. A Boulle G Van Cutsem K Hilderbrand C Cragg M Abrahams S Mathee N Ford L Knight M Osler J Myers E Goemaere D Coetzee G Maartens, AIDS 2010 24 4 563 572 10.1097/QAD.0b013e328333bfb7 20057311
27. More than five million people receiving HIV treatment: WHO advises earlier treatment among people with HIV approach. World Health Organization, XVIII International AIDS Conference 2010 Vienna, Austria 2010
28. Predictors of outpatient medical appointment attendance among persons with HIV. SL Catz JB McClure GN Jones PJ Brantley, AIDS Care 1999 11 3 361 373 10.1080/09540129947983 10474634
29. Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. D Israelski C Gore-Felton R Power MJ Wood C Koopman, Prev Med 2001 33 5 470 475 10.1006/pmed.2001.0917 11676589
30. Early appointment adherence among persons living with HIV. JB McClure SL Catz PJ Brantley, AIDS Behavior 1999 3 2 157 165 10.1023/A:1025492108281 (Pubitemid 29316242)
31. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. C Arici D Ripamonti F Maggiolo M Rizzi MG Finazzi P Pezzotti F Suter, HIV Clin Trials 2002 3 1 52 57 10.1310/2XAK-VBT8-9NU9-6VAK 11819186
32. Antiretroviral therapy adherence in Brazil. MI Nemes HB Carvalho MF Souza, AIDS 2004 18 Suppl 3 15 S20 10.1097/00002030-200406003-00004 15322479
33. Older Age and the Response to and Tolerability of Antiretroviral Therapy. MJ Silverberg W Leyden MA Horberg GN DeLorenze D Klein CP Quesenberry, Arch Intern Med 2007 167 684 691 10.1001/archinte.167.7.684 17420427
34. Response to combination antiretroviral therapy: variation by age. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, AIDS 2008 22 1463 1473 10.1097/QAD.0b013e3282f88d02 18614870
35. AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. B Ledergerber M Egger V Erard R Weber B Hirschel H Furrer M Battegay P Vernazza E Bernasconi M Opravil D Kaufmann P Sudre P Francioli A Telenti, JAMA 1999 282 23 2220 2226 10.1001/jama.282.23.2220 10605973
36. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. SD Lawn F Little L Bekker R Kaplan E Campbel E Orrell R Wood, AIDS 2009 23 3 335 342 10.1097/QAD.0b013e328321823f 19114870
37. CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. BH Chi M Giganti PL Mulenga M Limbada SE Reid W Mutale JS Stringer, JAIDS 2009 52 1 125 131 19546812
38. A characterisation of patient drop outs in a cohort of HIV positive homosexual/bisexual men and intravenous drug users. WK Poole R Perritt KB Shah Y Lou J Turner P Kvale PC Hopewell J Glassroth M Rosen L Reichman J Wallace, J Epidemiol Community Health 2001 55 1 66 67 10.1136/jech.55.1.66 11112953
39. Factors associated with engaging socially marginalized HIV-positive persons in primary care. MH Rumptz C Tobias S Rajabiun JB Bradford HJ Cabral R Young WE Cunningham, AIDS Patient Care STDS 2007 21 1 30 39 10.1089/apc.2007. 9989 17263651
40. Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a cross-sectional study of cost, stigma, and perceptions about ART. MP Fox A Mazimba P Seidenberg D Crooks B Sikateyo S Rosen, Journal of the International AIDS Society 2010 13 8 10.1186/1758-2652-13-8 20205930